Hvivo Share Price (HVO)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Hvivo Plc	LSE:HVO	London	Ordinary Share	GB00B9275X97	ORD 0.1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.45	3.78%	12.35	1,296,064	14:00:25

Bid Price		Offer Price	High Price	Low Price	Open Price
12.20		12.50	12.35	11.90	11.90

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	11.03	-18.86	-21.30		10

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
16:28:41	O	671	12.23	GBX

Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Salvarx (SALV), Sensyne Health (SENS)

Hvivo (HVO) Latest News

Hvivo News

Date	Time	Source	Headline
17/11/2022	14:05	UKREG	hVIVO PLC Second Price Monitoring Extn
17/11/2022	14:00	UKREG	hVIVO PLC Price Monitoring Extension
11/11/2022	07:00	UKREG	hVIVO PLC Exercise of Options
10/11/2022	21:19	ALNC	TRADING UPDATES: Zambeef expects profit jump; Mobile Streams wins deal
10/11/2022	11:00	UKREG	hVIVO PLC Price Monitoring Extension
10/11/2022	08:22	UKREG	hVIVO PLC GBP13.6m RSV antiviral contract
04/11/2022	07:25	UKREG	hVIVO PLC Holding(s) in Company
25/10/2022	13:53	ALNC	TRADING UPDATES: Gunsynd invests; AQRU launches crypto-backed loans
25/10/2022	06:00	UKREG	Open Orphan PLC Change of name to hVIVO plc effective
20/10/2022	06:00	UKREG	Open Orphan PLC Capital Markets Day

More Hvivo News

Hvivo Investors Hvivo Takeover Rumours

Hvivo (HVO) Share Charts 1 Year Hvivo Chart
1 Month Hvivo Chart	Intraday Hvivo Chart

Hvivo (HVO) Discussions and Chat

Hvivo Forums and Chat

Date	Time	Title	Posts
04/12/2022	22:05	hVIVO plc	603
26/10/2022	07:49	hVIVO plc	2,750

Add a New Thread

Hvivo (HVO) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Hvivo trades in real-time

Hvivo (HVO) Top Chat Posts

Top Posts
Posted at 04/12/2022 08:20 by Hvivo Daily Update Hvivo Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 11.90p. Hvivo Plc has a 4 week average price of 9.25p and a 12 week average price of 8.57p. The 1 year high share price is 24.75p while the 1 year low share price is currently 8.57p. There are currently 83,664,276 shares in issue and the average daily traded volume is 1,062,990 shares. The market capitalisation of Hvivo Plc is £10,332,538.09. Read Full Thread Reply
Posted at 22/11/2022 20:48 by garth sikhthetech22 Nov '22 - 17:12 - 500 of 503 0 0 0 The share price is where it was only a few months ago. Since then it fell after the H1 results and no news since last week to justify the significant rise. Sikh, I think you might be looking at this through the wrong end. From the end I'm looking at it through: Decent results and another contract and the share price fell without justification. Nothing to justify the fall except wider market gravity. The share price is now normalising. No other explanation needed. Except that I would add that when I read Simon Thompson's piece I wondered about the timing of its release. I.e. was it timed to align with a point at which a known and long present line of stock was drying up? That last bit is pure conjecture on my part though. G. Read Full Thread Follow Reply
Posted at 21/11/2022 18:32 by sikhthetech Rivaldo, "With £53m of of the forecast 2023 £56m revenues already covered per Finncap there must be a good chance that HVO will beat expectations next year." Rampers were saying similar last year(then called Orph) for fy2022 revenue. It didn't make any difference, did it?. In fact the share price still continued on the downtrend as expectations were missed, as usual. Why should it be any different this time? The fact, as recent contract rns shows, is any new work will commence towards end of 2023 and revenue will be recognised in 2024, with some in 2023. The fy2023 results probably announced in June 2024 (if they keep to same timetable as before), so 18months away and fy2024 in June 2025, so 2.5yrs away!!!!! from 10th Nov: " The study is expected to commence in Q3/Q4 2023, with the revenue being recognised in 2023 and 2024." https://uk.advfn.com/stock-market/london/hvivo-HVO/share-news/hVIVO-PLC-GBP13-6m-RSV-antiviral-contract/89515966 Read Full Thread Follow Reply
Posted at 21/11/2022 16:01 by sikhthetech Don't take my word for it, readers should check the performance and shares for themselves.. sikhthetech - 14 Nov 2022 - 12:51:46 - 226 of 302 hVIVO plc - HVO 1gw, Why you haven't commented on trmr's dismal Q3 results? The share price crashed around 30% so far. That follows your usual performance, where your shares crash on facts/results. Shameful. Other shares performance as of couple months ago: https://uk.advfn.com/cmn/fbb/thread.php3?id=49342172&from=4915&to=4915 Read Full Thread Follow Reply
Posted at 21/11/2022 15:24 by parob Makes a huge difference once you break the trading range. Even Simon Thompson mentioned it in his buy recommendation: "It's also worth noting that the share price seems to have finally formed a base in the 9p to 10.6p trading range, having deflated from a bubble valuation during Covid-19 lockdowns when day traders sent the shares soaring way above their intrinsic value. A share price break-out above the top of that trading range would be a strong signal that the consolidation period is finally over. Buy." Read Full Thread Follow Reply
Posted at 21/11/2022 13:14 by sikhthetech Rivaldo, "With £53m of of the forecast 2023 £56m revenues already covered per Finncap there must be a good chance that HVO will beat expectations next year." Rampers were saying similar last year(when these were Orph) for fy2022 revenue. It didn't make any difference. In fact the share price still continued it downtrend as expectations were missed, as usual. The fact, as recent contract rns shows, is any new work will commence towards end of 2023 and revenue will be recognised in 2024, with some in 2023. The fy2023 results probably announced in June 2024 (if they keep to same timetable as before), so 18months away and fy2024 in June 2025, so 2.5yrs away!!!!! from 10th Nov: " The study is expected to commence in Q3/Q4 2023, with the revenue being recognised in 2023 and 2024." https://uk.advfn.com/stock-market/london/hvivo-HVO/share-news/hVIVO-PLC-GBP13-6m-RSV-antiviral-contract/89515966 owenski - 10 Dec 2021 - 09:15:38 - 570 of 5589 OPEN ORPHAN Next years guidance in the £50m region, margins expected to be improving to possibly 30 - 35% Some Covid work is reckoned to be on top of that - quantity unknown at this stage. 80% of next years revenues already secured - how many companies are in that kind of sweet spot. A further 4 to 5 influenza studies in contract negotiation - size between 4 to 12m Malarial study being negotiated. Other studies in the pipeline. OO in a sweet spot with products to sell in a growing market. Potential upside from spinouts still to come for free. These are being pumped/dumped by the blnx(now trmr) gang. Look at trmr thread, no posts, yet it's busy here. Read Full Thread Follow Reply
Posted at 21/11/2022 08:27 by parob Yes Garth, it would have a big impact on the share price if another large contract is announced. And ST would love it.Well I have increased my personal exit target price over the weekend from 20p to 24p. Simon Thompson's conservative 19p + £30M (5p) for DIM and HVO's share of Imutex and PrEP Bio. Read Full Thread Follow Reply
Posted at 19/11/2022 08:33 by parob Good post courtesy of Silverfox1963 on lse yesterday: Simon Thompson places a conservative valuation on HVO of 19p per share but this is just for the core business. He acknowledges that in addition to this there are a number of "hidden balance sheet value" items namely DIM and HVO's share of Imutex and PrEP Bio. He notes rightly that market conditions are not conducive to monetising the value in these assets right now and that it is difficult to value them. Nevertheless "FinnCap has given it a stab, valuing them at £60m, or almost the same as Hvo's entire market cap." This is what excites me. It may take time but the value of these assets is not reflected at all in HVO's share price and one day CF will, I am sure, "surprise and delight" shareholders by monetising these assets. Read Full Thread Follow Reply
Posted at 17/11/2022 12:39 by sikhthetech There you go, as expected... Beware of the pump and dump.. Look at the trades...lots of small groups of trades within seconds of each other to push the share price higher. Checkout trmr, byot, nano, sar etc.. 1gw's mates use the same tactics, to make it look like there's interest.. they then sell.. Check the posts yourselves. https://uk.advfn.com/cmn/fbb/thread.php3?id=44682089&from=405 sikhthetech - 14 Nov 2022 - 12:51:46 - 226 of 302 hVIVO plc - HVO 1gw, Why you haven't commented on trmr's dismal Q3 results? The share price crashed around 30% so far. That follows your usual performance, where your shares crash on facts/results. Shameful. Other shares performance as of couple months ago: https://uk.advfn.com/cmn/fbb/thread.php3?id=49342172&from=4915&to=4915 Read Full Thread Follow Reply
Posted at 15/11/2022 11:49 by 1gw Chica1 - On Polb I don't know, just glad to see the rally. Sentiment is a funny thing. I think the newsflow helps, as do JS's upbeat presentations where he points out all that they have done since float. What we don't know is how much work has been going on behind the scenes to woo institutional investors, and that may also be a factor. My benchmark for POLB is the XBI index. Clearly POLB shareprice moved down broadly in line with XBI until around June which was a bit odd given it had so much of its market cap in cash - and specifically cash that was there to acquire assets, not just fund existing programs. So I thought that all else being equal, it should have moved down at half the pace of the XBI (50% cash at float), or maybe done even better since the market could expect them to pick up distressed biotech assets with their cash, positioning them for any rebound in biotech. Then POLB underperformed the XBI significantly between around June and end-September. Was that some HVO-heritage investors throwing in the towel when it got down to around 50% float price? Recently it has bounced back spectacularly, and there may well be a bit of momentum investing helping it along now as well as the "fundamental" newsflow. POLB is biotech, and very small cap at that, so volatility is to be expected. And whatever anyone says about POLB-001 being "likely" to succeed in its trials, these trials are binary outcomes and many a drug has failed a trial that its advocates thought it would pass. If POLB-001 does fail then the shareprice is likely to see a big hit, although the new targets coming out of the AI program mean that the company is likely to be able to build a multi-asset pipeline to insulate itself a bit from individual trial outcomes. Probably on the wrong thread this, I know, but as many HVO holders are also POLB holders, and HVO has other biotech assets it would like to monetise, I think it's reasonable to post it here. No advice intended, of course. Read Full Thread Follow Reply
Posted at 10/11/2022 11:03 by adorling Having read the Liberum broker note published after the capital markets day I am more than confident the 21.6p target price they set will be reached in the next 2-3 months given today’s £13.6m RSV Contract win is not included in their numbers. Also from a technical viewpoint the HVO chart is a textbook BOWL formation and one of the best I have seen in the past 2 years so 40p should be possible in 2023 with several more significant Contracts announced and maybe a Corporate Action or two as well? Do not let the ignorant shorters on here create doubt in your mind as they will pay a very expensive price for their error of judgement going forward into 2023 as positions are reversed and we get that momentum in share price upwards as they have to “buy to close”. If you are a LTH who has topped up under 10p then there are a definitely a few bags to be made over the 1-3 year timeline IMO. Read Full Thread Follow Reply

Hvivo share price data is direct from the London Stock Exchange

Your Recent History

LSE

HVO

Hvivo

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Advertise Here

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20221205 01:23:35